Amyris, Inc. provides various alternatives to a range of petroleum-sourced products worldwide. The company uses its industrial bioscience technology to design microbes primarily yeast, as well as to convert plant-sourced sugars into renewable ingredients. It produces and sells Biofene that converts to squalane, which is used as an emollient in cosmetics and other personal care products; and natural oils and aroma chemicals for the flavors and fragrances market. The company also provides renewable solvents, polymers, and lubricants for industrial markets; Biofene ingredients for nutraceuticals and vitamins market; and renewable fuels for transportation fuels markets. It has a collaboration partnership with Total S.A. to produce and commercialize Biofene-based diesel and jet fuels. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was founded in 2003 and is headquartered in Emeryville, California.
Industry, Sector and Symbol
Industry Industrial organic chemicals
Sub-IndustryOil & Gas Refining & Marketing
SectorBasic Materials
SymbolNASDAQ:AMRS
CUSIP03236M10
Phone510-450-0761
Debt
Debt-to-Equity Ratio-0.35
Current Ratio0.67
Quick Ratio0.62
Price-To-Earnings
Trailing P/E Ratio-1.76
Forward P/E Ratio-2.80
P/E GrowthN/A
Sales & Book Value
Annual Sales$143.45 million
Price / Sales1.88
Cash FlowN/A
Price / CashN/A
Book Value($4.64) per share
Price / Book-1.16
Profitability
EPS (Most Recent Fiscal Year)($3.05)
Net Income$-72,320,000.00
Net Margins-85.70%
Return on EquityN/A
Return on Assets-125.68%
Miscellaneous
Employees414
Outstanding Shares50,180,000
Amyris (NASDAQ:AMRS) Frequently Asked Questions
What is Amyris' stock symbol?
Amyris trades on the NASDAQ under the ticker symbol "AMRS."
When did Amyris' stock split? How did Amyris' stock split work?
Amyris's stock reverse split before market open on Tuesday, June 6th 2017. The 1-15 reverse split was announced on Tuesday, June 6th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 5th 2017. An investor that had 100 shares of Amyris stock prior to the reverse split would have 7 shares after the split.
How were Amyris' earnings last quarter?
Amyris Inc (NASDAQ:AMRS) released its quarterly earnings results on Monday, May, 14th. The biotechnology company reported ($1.79) EPS for the quarter, missing the consensus estimate of ($0.48) by $1.31. The biotechnology company earned $23 million during the quarter, compared to analyst estimates of $24.12 million. The company's revenue was up 77.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.13) earnings per share. View Amyris' Earnings History.
When is Amyris' next earnings date?
What price target have analysts set for AMRS?
3 brokerages have issued 12-month price targets for Amyris' shares. Their forecasts range from $4.00 to $15.00. On average, they anticipate Amyris' share price to reach $9.6667 in the next year. View Analyst Ratings for Amyris.
Who are some of Amyris' key competitors?
Some companies that are related to Amyris include Green Plains (GPRE), Codexis (CDXS), Westlake Chemical Partners (WLKP), Renewable Energy Group (REGI), FutureFuel (FF), Green Plains Partners (GPP), REX American Resources (REX), Sino United Worldwide Consolidated (SUIC), Pacific Ethanol (PEIX), Tantech (TANH), China Insonline (WAYS), Aemetis (AMTX), CTD (CTDH), OriginClear (OCLN) and Gevo (GEVO).
Who are Amyris' key executives?
Amyris' management team includes the folowing people:
- Mr. John G. Melo, Pres, CEO & Director (Age 52)
- Ms. Kathleen Valiasek, Chief Financial Officer (Age 54)
- Mr. Eduardo Alvarez, Chief Operating Officer (Age 54)
- Mr. Nicole Kelsey, Gen. Counsel & Sec. (Age 51)
- Dr. Joel R. Cherry, Pres of R&D (Age 57)
Has Amyris been receiving favorable news coverage?
News headlines about AMRS stock have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies negative and positive media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Amyris earned a media sentiment score of 0.16 on Accern's scale. They also assigned media coverage about the biotechnology company an impact score of 43.76 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.
Who are Amyris' major shareholders?
Amyris' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include TEMASEK HOLDINGS (PRIVATE) LTD (8.90%), Millennium Management LLC (0.49%), Crown Advisors Management Inc. (0.20%), JPMorgan Chase & Co. (0.20%), KBC Group NV (0.13%) and BlackRock Inc. (0.11%). Company insiders that own Amyris stock include (Mauritius) Pte Ltd Maxwell, John Melo and Patrick Y Yang. View Institutional Ownership Trends for Amyris.
Which major investors are buying Amyris stock?
AMRS stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, Crown Advisors Management Inc., JPMorgan Chase & Co., Barclays PLC, Tibra Equities Europe Ltd, B. Riley Financial Inc., Element Capital Management LLC and BlackRock Inc.. View Insider Buying and Selling for Amyris.
How do I buy shares of Amyris?
Shares of AMRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Amyris' stock price today?
One share of AMRS stock can currently be purchased for approximately $5.37.
How big of a company is Amyris?
Amyris has a market capitalization of $272.46 million and generates $143.45 million in revenue each year. The biotechnology company earns $-72,320,000.00 in net income (profit) each year or ($3.05) on an earnings per share basis. Amyris employs 414 workers across the globe.
How can I contact Amyris?
Amyris' mailing address is 5885 HOLLIS STREET SUITE 100, EMERYVILLE CA, 94608. The biotechnology company can be reached via phone at 510-450-0761 or via email at [email protected]
MarketBeat Community Rating for Amyris (AMRS)
MarketBeat's community ratings are surveys of what our community members think about Amyris and other stocks. Vote "Outperform" if you believe AMRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMRS will underperform the S&P 500 over the long term. You may vote once every thirty days.
